Netherlands

Smart Site Selection for Life Sciences Companies

Life science companies have to future-proof their value chain by placing functions, assets and risks in locations where they are planning to have their profits taxed. Structures where profit allocations are made in tax-beneficent locations with little or no substance are no longer viable.
8

Integrierte Versorgung am Beispiel von Groningen

Die alternde Bevölkerung, die starke Zunahme von chronischen Erkrankungen sowie der technologische Fortschritt, haben einen starken Einfluss auf die bestehenden Strukturen der Leistungserbringung. In diesem Artikel wird anhand eines Beispiels von Groningen in den Niederlanden aufgezeigt, wie eine nutzbringende, integrierte Versorgung umgesetzt werden konnte.
3

How attractive are European Life Sciences Sites?

KPMG’s newest report on leading Life Sciences Clusters in Europe, released on 3 November 2015 at the Bio Europe Congress, reveals important differences between different countries in Europe and their attractiveness for Foreign Direct Investments for the Life Sciences Industry.
16

Life Sciences Clusters in Europe

What makes a European Life Science site attractive to foreign investors? KPMG Switzerland’s Global Location Evaluation Services collaborated with Venture Valuation, a business intelligence boutique specializing in Life Sciences (LS), to analyze previously unpublished data comparing leading European LS clusters.
7